The clinical question

Preserving joint structure and function is the clinical question behind this program. The development objective is to evaluate whether local delivery of a regenerative payload can support cartilage repair.

Our research approach

The candidate combines an FGF18 payload with mesenchymal stromal cells (MSCs), using mRNA to program transient protein expression. Expression, potency, local exposure and product consistency are central development questions.

Current development focus

Current work focuses on product definition, expression and functional assessment, and a product-specific preclinical evidence package. Scientific review or studies of other MSC or extracellular-vesicle products do not establish clinical validation of FGF18–MSC.

Questions that guide development

  • Can FGF18 expression be reproduced across manufacturing batches?
  • Does the engineered product show a benefit over the unmodified cell comparator?
  • Which dose, local exposure and functional endpoints justify further development?
This is an investigational research program. No clinical efficacy, completed clinical filing or commercial authorization is implied.